Abstract
Polyuria–polydipsia syndrome can be caused by central diabetes insipidus, nephrogenic diabetes insipidus or primary polydipsia. To avoid confusion with diabetes mellitus, the name ‘central diabetes insipidus’ was changed in 2022 to arginine vasopressin (AVP) deficiency and ‘nephrogenic diabetes insipidus’ was renamed as AVP resistance. To differentiate the three entities, various osmotic and non-osmotic copeptin-based stimulation tests have been introduced in the past decade. The hypertonic saline test plus plasma copeptin measurement emerged as the test with highest diagnostic accuracy, replacing the water deprivation test as the gold standard in differential diagnosis of the polyuria–polydipsia syndrome. The mainstay of treatment for AVP deficiency is AVP replacement with desmopressin, a synthetic analogue of AVP specific for AVP receptor 2 (AVPR2), which usually leads to rapid improvements in polyuria and polydipsia. The main adverse effect of desmopressin is dilutional hyponatraemia, which can be reduced by regularly performing the so-called desmopressin escape method. Evidence from the past few years suggests an additional oxytocin deficiency in patients with AVP deficiency. This potential deficiency should be further evaluated in future studies, including feasible provocation tests for clinical practice and interventional trials with oxytocin substitution.
Key points
-
Central diabetes insipidus has been renamed to arginine vasopressin (AVP) deficiency and nephrogenic diabetes insipidus to AVP resistance.
-
Polyuria–polydipsia syndrome comprises AVP deficiency or resistance and primary polydipsia.
-
Copeptin-based stimulation tests have simplified and improved the diagnostic procedure for AVP deficiency and of these, the hypertonic saline test with measurement of plasma levels of copeptin has the highest diagnostic accuracy.
-
AVP deficiency can be treated with desmopressin, but this treatment confers a risk of hyponatraemia; patients should be instructed to use the desmopressin escape method to decrease the risk of hyponatraemia.
-
Oxytocin deficiency can occur in patients with AVP deficiency and can be assessed via stimulation with 3,4-methylenedioxymethamphetamine (that is, MDMA); whether oxytocin treatment is a future option for patients with AVP deficiency should be investigated in larger studies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
References
Christ-Crain, M. et al. Diabetes insipidus. Nat. Rev. Dis. Prim. 5, 54 (2019). This review outlines diagnosis and treatment of diabetes insipidus (arginine vasopressin deficiency and arginine vasopressin resistance) and primary polydipsia.
Mutter, C. M. et al. Diabetes insipidus: pathogenesis, diagnosis, and clinical management. Cureus 13, e13523 (2021).
Prentice, M. Time for change: renaming diabetes insipidus to improve patient safety. Clin. Endocrinol. 88, 625–626 (2018).
Atila, C. et al. Central diabetes insipidus from a patient’s perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol. 10, 700–709 (2022). A study presenting data on psychological comorbidities and treatment adverse effects from a web-based survey in >1,000 patients with arginine vasopressin deficiency.
Arima, H. et al. Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus. J. Clin. Endocrinol. Metab. 108, 1–3 (2022).
Fenske, W. et al. A copeptin-based approach in the diagnosis of diabetes insipidus. N. Engl. J. Med. 379, 428–439 (2018). A multicentre diagnostic study that shows the superiority of the hypertonic saline-stimulated copeptin test compared with the indirect water deprivation test in the differential diagnosis of the polyuria–polydipsia syndrome.
Winzeler, B. et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet 394, 587–595 (2019). A diagnostic study showing a high diagnostic accuracy of the arginine-stimulated copeptin test in the differential diagnosis of the polyuria–polydipsia syndrome.
Refardt, J. et al. Arginine or hypertonic saline-stimulated copeptin to diagnose AVP deficiency. N. Engl. J. Med. 389, 1877–1887 (2023). A head-to-head comparison of hypertonic saline versus arginine-stimulated copeptin tests that demonstrates the superiority of the hypertonic saline test in the differential diagnosis of the polyuria–polydipsia syndrome.
Atila, C. et al. Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case–control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diabetes Endocrinol. 11, 454–464 (2023). A study that provides evidence for an oxytocin deficiency in patients with arginine vasopressin deficiency.
Lindholm, J. Diabetes insipidus: historical aspects. Pituitary 7, 33–38 (2004).
Robertson, G. L. The regulation of vasopressin function in health and disease. Recent Prog. Horm. Res. 33, 333–385 (1976).
Miller, M., Dalakos, T., Moses, A. M., Fellerman, H. & Streeten, D. H. Recognition of partial defects in antidiuretic hormone secretion. Ann. Intern. Med. 73, 721–729 (1970).
Bockenhauer, D. & Bichet, D. G. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat. Rev. Nephrol. 11, 576–588 (2015).
Sailer, C., Winzeler, B. & Christ-Crain, M. Primary polydipsia in the medical and psychiatric patient: characteristics, complications and therapy. Swiss Med. Wkly 147, w14514 (2017).
Cadnapaphornchai, M. A. et al. Effect of primary polydipsia on aquaporin and sodium transporter abundance. Am. J. Physiol. Ren. Physiol. 285, F965–F971 (2003).
Robertson, G. L. Differential diagnosis of polyuria. Annu. Rev. Med. 39, 425–442 (1988).
Verbalis, J. G. Disorders of body water homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 17, 471–503 (2003).
Thompson, C. J. & Baylis, P. H. Thirst in diabetes insipidus: clinical relevance of quantitative assessment. Q. J. Med. 65, 853–862 (1987).
Sailer, C. O. et al. Characteristics and outcomes of patients with profound hyponatraemia due to primary polydipsia. Clin. Endocrinol. 87, 492–499 (2017).
Arslan, A., Karaarslan, E. & Dinçer, A. High intensity signal of the posterior pituitary. A study with horizontal direction of frequency-encoding and fat suppression MR techniques. Acta Radiol. 40, 142–145 (1999).
Moses, A. M., Clayton, B. & Hochhauser, L. Use of T1-weighted MR imaging to differentiate between primary polydipsia and central diabetes insipidus. Am. J. Neuroradiol. 13, 1273–1277 (1992).
Klyn, V. et al. Presence of the posterior pituitary bright spot sign on MRI in the general population: a comparison between 1.5 and 3 T MRI and between 2D-T1 spin-echo- and 3D-T1 gradient-echo sequences. Pituitary 21, 379–383 (2018).
Maghnie, M. et al. Central diabetes insipidus in children and young adults. N. Engl. J. Med. 343, 998–1007 (2000).
Hannon, M. et al. Anterior hypopituitarism is rare and autoimmune disease is common in adults with idiopathic central diabetes insipidus. Clin. Endocrinol. 76, 725–728 (2011).
Bonneville, J. F. Magnetic resonance imaging of pituitary tumors. Front. Horm. Res. 45, 97–120 (2016).
Leger, J., Velasquez, A., Garel, C., Hassan, M. & Czernichow, P. Thickened pituitary stalk on magnetic resonance imaging in children with central diabetes insipidus. J. Clin. Endocrinol. Metab. 84, 1954–1960 (1999).
Block, L. H., Furrer, J., Locher, R. A., Siegenthaler, W. & Vetter, W. Changes in tissue sensitivity to vasopressin in hereditary hypothalamic diabetes insipidus. Klin. Wochenschr. 59, 831–836 (1981).
Fenske, W. & Allolio, B. Clinical review: current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J. Clin. Endocrinol. Metab. 97, 3426–3437 (2012).
Fenske, W. et al. Copeptin in the differential diagnosis of the polydipsia–polyuria syndrome — revisiting the direct and indirect water deprivation tests. J. Clin. Endocrinol. Metab. 96, 1506–1515 (2011).
Zerbe, R. L. & Robertson, G. L. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N. Engl. J. Med. 305, 1539–1546 (1981).
Robertson, G. L., Mahr, E. A., Athar, S. & Sinha, T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J. Clin. Invest. 52, 2340–2352 (1973).
Morgenthaler, N. G., Struck, J., Alonso, C. & Bergmann, A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52, 112–119 (2006).
Czaczkes, J. W. & Kleeman, C. R. The effect of various states of hydration and the plasma concentration on the turnover of antidiuretic hormone in mammals. J. Clin. Invest. 43, 1649–1658 (1964).
Holwerda, D. A. A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur. J. Biochem. FEBS 28, 334–339 (1972).
Levy, B., Chauvet, M. T., Chauvet, J. & Acher, R. Ontogeny of bovine neurohypophysial hormone precursors. II. Foetal copeptin, the third domain of the vasopressin precursor. Int. J. Pept. Protein Res. 27, 320–324 (1986).
Balanescu, S. et al. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J. Clin. Endocrinol. Metab. 96, 1046–1052 (2011).
Sailer, C. O. et al. Validity of different copeptin assays in the differential diagnosis of the polyuria–polydipsia syndrome. Sci. Rep. 11, 10104 (2021).
Morgenthaler, N. G. et al. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28, 219–226 (2007).
Szinnai, G. et al. Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J. Clin. Endocrinol. Metab. 92, 3973–3978 (2007).
Katan, M. et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann. Neurol. 66, 799–808 (2009).
Reichlin, T. et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J. Am. Coll. Cardiol. 54, 60–68 (2009).
Katan, M. & Christ-Crain, M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med. Wkly 140, w13101 (2010).
Urwyler, S. A., Schuetz, P., Sailer, C. & Christ-Crain, M. Copeptin as a stress marker prior and after a written examination — the CoEXAM study. Stress 18, 134–137 (2015).
Brooks, E. et al. Copeptin is increased by nausea and vomiting during hypertonic saline infusion in healthy individuals. Clin. Endocrinol. 94, 820–826 (2021).
Fenske, W. K. et al. Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers. J. Clin. Endocrinol. Metab. 103, 505–513 (2018).
Timper, K. et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria–polydipsia syndrome: a prospective multicenter study. J. Clin. Endocrinol. Metab. 100, 2268–2274 (2015).
Merimee, T. J., Rabinowtitz, D. & Fineberg, S. E. Arginine-initiated release of human growth hormone. Factors modifying the response in normal man. N. Engl. J. Med. 280, 1434–1438 (1969).
Nair, N. P. et al. Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Prog. Neuropsychopharmacol. Biol. Psychiatry 9, 633–637 (1985).
Atila, C. et al. Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind, randomized, placebo-controlled study. Eur. J. Endocrinol. 187, 65–74 (2022).
Urwyler, S. A. et al. Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers. Pituitary 24, 555–563 (2021).
Behan, L. A. et al. Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study. Eur. J. Endocrinol. 172, 243–250 (2015).
Pedersen, A. N., Krogh, J., Andreassen, M. & Rasmussen, A. K. Desmopressin dose requirements in adults with congenital and acquired central diabetes insipidus. Horm. Metab. Res. 56, 206–213 (2023).
Baldeweg, S. E. et al. Society for Endocrinology Clinical Guidance: inpatient management of cranial diabetes insipidus. Endocr. Connect. 7, G8–G11 (2018).
Richardson, D. W. & Robinson, A. G. Desmopressin. Ann. Intern. Med. 103, 228–239 (1985).
Achinger, S. G., Arieff, A. I., Kalantar-Zadeh, K. & Ayus, J. C. Desmopressin acetate (DDAVP)-associated hyponatremia and brain damage: a case series. Nephrol. Dial. Transplant. 29, 2310–2315 (2014).
Bichet, D. G. Regulation of thirst and vasopressin release. Annu. Rev. Physiol. 81, 359–373 (2019).
Kim, G. H. Pathophysiology of drug-induced hyponatremia. J. Clin. Med. 11, 5810 (2022).
Tomkins, M., Lawless, S., Martin-Grace, J., Sherlock, M. & Thompson, C. J. Diagnosis and management of central diabetes insipidus in adults. J. Clin. Endocrinol. Metab. 107, 2701–2715 (2022).
Teare, H. et al. Challenges and improvement needs in the care of patients with central diabetes insipidus. Orphanet. J. Rare Dis. 17, 58 (2022).
Christ-Crain, M., Winzeler, B. & Refardt, J. Diagnosis and management of diabetes insipidus for the internist: an update. J. Intern. Med. 290, 73–87 (2021).
Melmed, S., Polonsky, K. S., Larsen, P. R. & Kronenberg, H. M. Williams Textbook of Endocrinology 14th edn (Elsevier, 2019).
Fukuda, I., Hizuka, N. & Takano, K. Oral DDAVP is a good alternative therapy for patients with central diabetes insipidus: experience of five-year treatment. Endocr. J. 50, 437–443 (2003).
Kataoka, Y., Nishida, S., Hirakawa, A., Oiso, Y. & Arima, H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. Endocr. J. 62, 195–200 (2015).
Althammer, F. & Grinevich, V. Diversity of oxytocin neurons: beyond magno- and parvocellular cell types? J. Neuroendocrinol. https://doi.org/10.1111/jne.12549 (2017).
Althammer, F., Eliava, M. & Grinevich, V. Central and peripheral release of oxytocin: relevance of neuroendocrine and neurotransmitter actions for physiology and behavior. Handb. Clin. Neurol. 180, 25–44 (2021).
Swanson, L. W. & Sawchenko, P. E. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Annu. Rev. Neurosci. 6, 269–324 (1983).
Zhang, B. et al. Reconstruction of the hypothalamo-neurohypophysial system and functional dissection of magnocellular oxytocin neurons in the brain. Neuron 109, 331–346.e7 (2021).
Knobloch, H. S. et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron 73, 553–566 (2012).
Mitre, M. et al. A distributed network for social cognition enriched for oxytocin receptors. J. Neurosci. 36, 2517–2535 (2016).
Oliveira, V. E. M. et al. Oxytocin and vasopressin within the ventral and dorsal lateral septum modulate aggression in female rats. Nat. Commun. 12, 2900 (2021).
Meyer-Lindenberg, A., Domes, G., Kirsch, P. & Heinrichs, M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 12, 524–538 (2011).
Menon, R. et al. Oxytocin signaling in the lateral septum prevents social fear during lactation. Curr. Biol. 28, 1066–1078.e66 (2018).
Ferretti, V. et al. Oxytocin signaling in the central amygdala modulates emotion discrimination in mice. Curr. Biol. 29, 1938–1953.e6 (2019).
Blevins, J. E., Schwartz, M. W. & Baskin, D. G. Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R87–R96 (2004).
Melis, M. R., Argiolas, A. & Gessa, G. L. Oxytocin-induced penile erection and yawning: site of action in the brain. Brain Res. 398, 259–265 (1986).
Petersson, M. Cardiovascular effects of oxytocin. Prog. Brain Res. 139, 281–288 (2002).
Sabatier, N., Leng, G. & Menzies, J. Oxytocin, feeding, and satiety. Front. Endocrinol. 4, 35 (2013).
Rash, J. A., Aguirre-Camacho, A. & Campbell, T. S. Oxytocin and pain: a systematic review and synthesis of findings. Clin. J. Pain 30, 453–462 (2014).
Eliava, M. et al. A new population of parvocellular oxytocin neurons controlling magnocellular neuron activity and inflammatory pain processing. Neuron 89, 1291–1304 (2016).
Hasan, M. T. et al. A fear memory engram and its plasticity in the hypothalamic oxytocin system. Neuron 103, 133–146.e8 (2019).
Tang, Y. et al. Social touch promotes interfemale communication via activation of parvocellular oxytocin neurons. Nat. Neurosci. 23, 1125–1137 (2020).
Mantella, R. C., Vollmer, R. R., Li, X. & Amico, J. A. Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology 144, 2291–2296 (2003).
Ferguson, J. N. et al. Social amnesia in mice lacking the oxytocin gene. Nat. Genet. 25, 284–288 (2000).
Koltowska-Häggström, M. et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life. Eur. J. Endocrinol. 155, 109–119 (2006).
Crespo, I., Valassi, E., Santos, A. & Webb, S. M. Health-related quality of life in pituitary diseases. Endocrinol. Metab. Clin. North Am. 44, 161–170 (2015).
Nozaki, A. et al. Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire. Endocrine 51, 140–147 (2016).
Karavitaki, N. et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin. Endocrinol. 62, 397–409 (2005).
Karavitaki, N., Cudlip, S., Adams, C. B. & Wass, J. A. Craniopharyngiomas. Endocr. Rev. 27, 371–397 (2006).
Wijnen, M. et al. Very long-term sequelae of craniopharyngioma. Eur. J. Endocrinol. 176, 755–767 (2017).
Pereira, A. M. et al. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin. Endocrinol. 62, 197–204 (2005).
Bhargava, R., Daughters, K. L. & Rees, A. Oxytocin therapy in hypopituitarism: challenges and opportunities. Clin. Endocrinol. 90, 257–264 (2019).
Eisenberg, Y. et al. Oxytocin alterations and neurocognitive domains in patients with hypopituitarism. Pituitary 22, 105–112 (2019).
Gebert, D. et al. De-masking oxytocin-deficiency in craniopharyngioma and assessing its link with affective function. Psychoneuroendocrinology 88, 61–69 (2018).
Daughters, K., Manstead, A. S. R. & Rees, D. A. Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability. Endocrine 57, 166–174 (2017).
Daubenbüchel, A. M. et al. Oxytocin in survivors of childhood-onset craniopharyngioma. Endocrine 54, 524–531 (2016).
Aulinas, A. et al. Low plasma oxytocin levels and increased psychopathology in hypopituitary men with diabetes insipidus. J. Clin. Endocrinol. Metab. 104, 3181–3191 (2019).
Leng, G. & Sabatier, N. Measuring oxytocin and vasopressin: bioassays, immunoassays and random numbers. J. Neuroendocrinol. https://doi.org/10.1111/jne.12413 (2016).
Valstad, M. et al. The correlation between central and peripheral oxytocin concentrations: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 78, 117–124 (2017).
Chiodera, P. et al. Hypoglycemia-induced arginine vasopressin and oxytocin release is mediated by glucoreceptors located inside the blood–brain barrier. Neuroendocrinology 55, 655–659 (1992).
Sailer, C. O. et al. Oxytocin levels in response to pituitary provocation tests in healthy volunteers. Eur. J. Endocrinol. 185, 355–364 (2021).
Brandi, M. L., Gebert, D., Kopczak, A., Auer, M. K. & Schilbach, L. Oxytocin release deficit and social cognition in craniopharyngioma patients. J. Neuroendocrinol. 32, e12842 (2020).
Holze, F. et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology 45, 462–471 (2020).
Kirkpatrick, M. G., Lee, R., Wardle, M. C., Jacob, S. & de Wit, H. Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology 39, 1654–1663 (2014).
Dolder, P. C., Müller, F., Schmid, Y., Borgwardt, S. J. & Liechti, M. E. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology 235, 467–479 (2018).
Vizeli, P. et al. Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. Front. Pharmacol. 13, 906639 (2022).
Verbalis, J. G. Oxytocin deficiency — a ‘new’ human disorder? Nat. Rev. Endocrinol. 19, 505–506 (2023).
Simmler, L. D. & Liechti, M. E. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. Handb. Exp. Pharmacol. 252, 143–164 (2018).
Hunt, G. E., McGregor, I. S., Cornish, J. L. & Callaghan, P. D. MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Res. Bull. 86, 65–73 (2011).
Schulze, L. et al. Oxytocin increases recognition of masked emotional faces. Psychoneuroendocrinology 36, 1378–1382 (2011).
Lischke, A. et al. Intranasal oxytocin enhances emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected. Psychoneuroendocrinology 37, 475–481 (2012).
Domes, G. et al. Effects of intranasal oxytocin administration on empathy and approach motivation in women with borderline personality disorder: a randomized controlled trial. Transl. Psychiatry 9, 328 (2019).
Quintana, D. S. et al. Oxytocin pathway gene networks in the human brain. Nat. Commun. 10, 668 (2019).
Wang, D., Yan, X., Li, M. & Ma, Y. Neural substrates underlying the effects of oxytocin: a quantitative meta-analysis of pharmaco-imaging studies. Soc. Cogn. Affect Neurosci. 12, 1565–1573 (2017).
Grace, S. A., Rossell, S. L., Heinrichs, M., Kordsachia, C. & Labuschagne, I. Oxytocin and brain activity in humans: a systematic review and coordinate-based meta-analysis of functional MRI studies. Psychoneuroendocrinology 96, 6–24 (2018).
Domes, G. et al. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol. Psychiatry 62, 1187–1190 (2007).
Striepens, N. et al. Oxytocin facilitates protective responses to aversive social stimuli in males. Proc. Natl Acad. Sci. USA 109, 18144–18149 (2012).
Leng, G. & Ludwig, M. Intranasal oxytocin: myths and delusions. Biol. Psychiatry 79, 243–250 (2016).
Churchland, P. S. & Winkielman, P. Modulating social behavior with oxytocin: how does it work? What does it mean. Horm. Behav. 61, 392–399 (2012).
Lee, M. R. et al. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nat. Commun. 11, 2783 (2020).
Lee, M. R. et al. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. Mol. Psychiatry 23, 115–122 (2018).
Smith, A. S., Korgan, A. C. & Young, W. S. Oxytocin delivered nasally or intraperitoneally reaches the brain and plasma of normal and oxytocin knockout mice. Pharmacol. Res. 146, 104324 (2019).
Bowen, M. T. Does peripherally administered oxytocin enter the brain? Compelling new evidence in a long-running debate. Pharmacol. Res. 146, 104325 (2019).
Cook, N., Miller, J. & Hart, J. Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma. J. Pediatr. Endocrinol. Metab. 29, 995–1000 (2016).
Hoffmann, A. et al. First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. Endocrine 56, 175–185 (2017).
Uvnäs Moberg, K. et al. Maternal plasma levels of oxytocin during breastfeeding — a systematic review. PLoS ONE 15, e0235806 (2020).
Uvnäs-Moberg, K. et al. Maternal plasma levels of oxytocin during physiological childbirth — a systematic review with implications for uterine contractions and central actions of oxytocin. BMC Pregnancy Childb. 19, 285 (2019).
Volz, J., Heinrich, U. & Volz-Köster, S. Conception and spontaneous delivery after total hypophysectomy. Fertil. Steril. 77, 624–625 (2002).
Shinar, S., Many, A. & Maslovitz, S. Questioning the role of pituitary oxytocin in parturition: spontaneous onset of labor in women with panhypopituitarism — a case series. Eur. J. Obstet. Gynecol. Reprod. Biol. 197, 83–85 (2016).
De Coopman, J. Breastfeeding after pituitary resection: support for a theory of autocrine control of milk supply? J. Hum. Lact. 9, 35–40 (1993).
Young, W. S. III et al. Deficiency in mouse oxytocin prevents milk ejection, but not fertility or parturition. J. Neuroendocrinol. 8, 847–853 (1996).
Aulinas, A. et al. Hypopituitarism and pregnancy: clinical characteristics, management and pregnancy outcome. Pituitary 25, 275–284 (2022).
Sowithayasakul, P., Boekhoff, S., Bison, B. & Müller, H. L. Pregnancies after childhood craniopharyngioma: results of KRANIOPHARYNGEOM 2000/2007 and review of the literature. Neuroendocrinology 111, 16–26 (2021).
Correa, F. A. et al. Successful pregnancies after adequate hormonal replacement in patients with combined pituitary hormone deficiencies. J. Endocr. Soc. 1, 1322–1330 (2017).
Bichet, D. G. & Verbalis, J. G. Arginine vasopressin deficiency (central diabetes insipidus): etiology, clinical manifestations, and postdiagnostic evaluation. UpToDate. Wolters Kluwer. https://www.uptodate.com/contents/arginine-vasopressin-deficiency-central-diabetes-insipidus-etiology-clinical-manifestations-and-postdiagnostic-evaluation (2023).
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
C.A., J.R. and M.C.-C. received occasional kits for copeptin measurements from Thermo Fisher AG, the manufacturer of the copeptin assay.
Peer review
Peer review information
Nature Reviews Endocrinology thanks Ashley Grossman and Susan Webb for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Atila, C., Refardt, J. & Christ-Crain, M. Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency. Nat Rev Endocrinol 20, 487–500 (2024). https://doi.org/10.1038/s41574-024-00985-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-024-00985-x
